KRAS and cancer: Target gene candidates in cancer therapy are mainly involved in oncogenes, angiogenesis and proliferation, like PLK1, EphA2, RRM2, KRAS, PKN3 and VEGF, which have been tested as target genes in early-phase clinical trials for RNAi-based cancer therapies [7].